

UpToDate & Lexicomp

Customer Success Specialist

Ginger 靜文

March 2021



Wolters Kluwer

Solutions to Reduce Unwanted Variability in Care

UpToDate®

*Evidence-based clinical
decision support for disease
and conditions*



Lexicomp®

*Pharmacological information and
medication decision support*

- ✓ Hospital-wide tool
- ✓ Design for clinicians

Together ...

these trusted brands provide the industry's most comprehensive medication and disease solution to support hospital clinicians' decision making and help enhance patient safety

What is Lexicomp?

- a **hospital-wide** drug reference solution providing clear, concise point-of-care drug information to help pharmacists, physicians and nurses reduce medication errors, improve efficiency and enhance patient safety.

- Dosing
- Interactions
- Administration
- I.V. Compatibility
- Warnings and precautions
- Clinical content
- Toxicology
- Medical Calculators
- Patient Education



Lexicomp Features Available in UpToDate

Feature	Lexicomp	UpToDate
	Full Lexi License	Lexicomp Features available as standard in UpToDate
Lexi-Drug Monographs	✓ Multi-National Drugs	✓ USA & Canada Drugs
Additional drug content sets (AHFS, Briggs, Infectious Disease, Allergy, Idiosyncratic Reactions, pharmacogenomics)	✓	✗
Patient Education Leaflets	✓	✗
Interactions	✓	✓ Does not include allergy and duplicate therapy
Drug Comparisons	✓	✗
Trissels IV	✓	✗
Toxicology	✓	✗
Drug Images	✓	✗
Lexicomp monograph specific Clinical Practice Guidelines	✓	✗
Integrated Formulary + Formulink License	✓ W/ Formulink License	✓ W/ Formulink License
Pharmacogenomics Content	✓	✗

Content Sets

- Lexi-Drugs*
- Lexi-Drugs Multinational*
- Pediatric and Neonatal Lexi-Drugs
- Geriatric Lexi-Drugs
- Lexi-Drugs International (Concise)
- AHFS Essentials (Adult and Pediatric)*/
- AHFS DI (Adult and Pediatric)*/
- Natural Products
- Pharmacogenomics
- Infectious Disease
- Lab Tests and Diagnostic Procedures
- Comparative Efficacy
- Class Monographs**
- Facts and Comparisons A to Z Drugs
- Facts and Comparisons Off-Label
- Facts and Comparisons REMS
- Drug Allergy and Idiosyncratic Reactions
- Pregnancy and Lactation, In-Depth
- Briggs Drugs in Pregnancy and Lactation*/

** = not available on mobile app.*

** = not available in the NA Provider Segment*

** = not available in the International Segment*

/ = licensed content

Comprehensive Coverage

- ✓ The full Lexicomp solution provides clinicians with a resource for more in-depth drug information.
- ✓ UpToDate only offers 20%-30% of content available in a full Lexicomp subscription.

The screenshot shows the Lexicomp website interface. At the top, there is a search bar with the text "Search Lexicomp" and a magnifying glass icon. Below the search bar, a navigation menu includes "Home", "Trisette's IV Compatibility", "Interactions", "Drug I.D.", "Patient Education", "Calculators", and "More Clinical Tools". The main content area displays "Search Results for 'Alteplase'". The results are organized into several categories, each with a link to "Alteplase" and a date indicating when the information was updated. Two specific results are highlighted with red boxes: "Lexi-Drugs Multinational" (updated 3/31/20) and "Pediatric and Neonatal Lexi-Drugs" (updated 5/18/20). Other categories include "Hospital Formulary", "AHFS Essentials (Adult and Pediatric)", "AHFS DI (Adult and Pediatric)", "Martindale: The Complete Drug Reference", "Geriatric Lexi-Drugs", "Patient Education - Disease and Procedure", "Patient Education - Adult Medication", "Patient Education - Pediatric Medication", "Facts and Comparisons A to Z Drugs", "Drug Allergy and Idiosyncratic Reactions", "Facts and Comparisons Off-Label", and "Briggs Drugs in Pregnancy and Lactation".

Lexicomp® Search Lexicomp

Home Trisette's IV Compatibility Interactions Drug I.D. Patient Education Calculators More Clinical Tools

Search Results for "Alteplase"

Hospital Formulary
Alteplase Dosing | Administration | Adverse Reactions Updated 5/18/20

Lexi-Drugs Multinational
Alteplase Dosing | Administration | Adverse Reactions Updated 3/31/20

Pediatric and Neonatal Lexi-Drugs
Alteplase Dosing | Administration | Adverse Reactions Updated 5/18/20

AHFS Essentials (Adult and Pediatric)
Alteplase Updated 3/2/20

AHFS DI (Adult and Pediatric)
Alteplase Updated 3/2/20

Martindale: The Complete Drug Reference
Alteplase
Alteplase for Injection USP 42

Geriatric Lexi-Drugs
Alteplase Updated 3/31/20

Patient Education - Disease and Procedure
Clot Dissolving Drugs for Heart Attack or Stroke Updated 3/23/20

Patient Education - Adult Medication
Alteplase

Patient Education - Pediatric Medication
Alteplase

Facts and Comparisons A to Z Drugs
Alteplase Updated 5/18/20


Drug Allergy and Idiosyncratic Reactions
Alteplase

Facts and Comparisons Off-Label
Alteplase: Frostbite Updated 3/11/20
Alteplase: Parapneumonic Pleural Effusion and Empyema Updated 3/31/20

Briggs Drugs in Pregnancy and Lactation
Alteplase

Mobile app

- **Virtually all information on the desktop version is included in the mobile app.**
- **All Lexicomp drug information modules are housed within one mobile app.**
- **Drug content downloads directly to mobile device, ensuring it's available if user loses cellular or wi-fi signal.**



Lexicomp has more Japan/European Drugs

Favipiravir (Lexi-Drugs Multinational)

Outline **Expand All**

- Special Alerts
 - Brand Names: International
- > Dosages
- > Uses
- Prescribing and Access Restrictions
- > Reproduction, Pregnancy, & Lactation
- > Adverse Reactions
- > Interactions
- > Preparations
- > Pearls & Related Information

Monograph Images

Special Alerts

- ▶ COVID-19 Important Updates March 2020

Brand Names: International

Avigan (JP)

Dosing: Adult

Note: Favipiravir is currently under investigation for use in the treatment of coronavirus disease 2019 (COVID-19) (See [ClinicalTrials.gov](https://clinicaltrials.gov)). At this time, safety and efficacy have not been established. However, preliminary dosing information based on the available published evidence and ongoing clinical trials is provided (Cai 2020; NIH 2020a; NIH 2020b). Whenever possible, treatment should be given as part of a clinical trial.

Coronavirus disease 2019 (COVID-19) (off-label use): Oral: Optimal dose and duration unknown, limited data available; 1,600 mg twice daily on day 1, followed by 600 mg twice daily for a total duration of 7 to 14 days (Cai 2020; NIH 2020a). Another clinical trial is using a dose of 2.4 g every 8 hours for 2 doses, followed by a dose of 1.2 g 8 hours later on day 1, followed by 1.2 g twice daily for a total duration of 7 to 14 days (NIH 2020b).

Lexicomp has more Herbal Products

Dong Quai (Natural Products Database)

Outline [Expand All](#)

Scientific Name

Scientific Family

Common Name(s)

> Clinical Overview

Botany

History

Chemistry

> Uses and Pharmacology

Dosing

> Pregnancy and Lactation

Monograph

Scientific Name

Angelica sinensis (Oliv.) Diels.

Scientific Family

- Apiaceae (carrot)

Common Name(s)

Chinese angelica; Danggui; Dong quai; Tang-kuei

Clinical Overview: Uses

Dong quai is used in combination with other plant extracts in Chinese traditional medicine as an analgesic for rheumatism, an allergy suppressant, and in the treatment of menstrual disorders. Dong quai and its chemical constituents possess antiasthmatic, antispasmodic, anti-inflammatory, and anticoagulant properties. Clinical trials supporting traditional uses are limited. It has also been used to flavor liqueurs and confections.

Alert box placed on the top

Trastuzumab (Lexi-Drugs Multinational)

Outline **Expand All**

Monograph

Images

Adult Patient Education

ALERT: US Boxed Warning

Brand Names: International

International Nonproprietary Names (INN)

Brazilian Nonproprietary Names (DCB)

Japanese Accepted Name (JAN)

Anatomic Therapeutic Chemical (ATC) Classification

Pharmacologic Category

▼ Dosages

Dosing: Adult

Dosing: Geriatric

Dosing: Renal Impairment: Adult

ALERT: US Boxed Warning

▼ **Cardiomyopathy:**

Trastuzumab product administration can result in subclinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens.

Evaluate left ventricular function in all patients prior to and during treatment with trastuzumab products. Discontinue trastuzumab treatment in patients receiving adjuvant therapy, and withhold trastuzumab in patients with metastatic disease for clinically significant decrease in left ventricular function.

▼ **Infusion reactions and pulmonary toxicity:**

Trastuzumab product administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of trastuzumab administration. Interrupt trastuzumab infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue trastuzumab for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome.

▼ **Pregnancy:**

Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception.

About our Evidence Based content-Off-Label Use

The screenshot displays the Lexicomp website interface. A search bar at the top contains the text 'Search Lexicomp'. The main content area is titled 'Amoxicillin and Clavulanate' and includes a sidebar with navigation options like 'Home', 'Triselle's IV Compat', 'Back To Search', 'Outline Expand All', 'Anatomic Therapeutic Chemical (ATC) Classification', 'Pharmacologic Category', 'Dosages', 'Uses', 'Comparative Efficacy', 'Clinical Practice Guidelines', and 'Administration and Storage'. The 'Uses' section is expanded, showing 'Use: Labeled Indications', 'Use: Off-Label: Adult', and 'Level of Evidence Definitions'. The 'Level of Evidence Definitions' section is highlighted with a red box and contains the following text:

Level of Evidence Definitions

Level of Evidence Scale

- A** - Consistent evidence from well-performed randomized, controlled trials or overwhelming evidence of some other form (eg, results of the introduction of penicillin treatment) to support the off-label use. Further research is unlikely to change confidence in the estimate of benefit.
- B** - Evidence from randomized, controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on confidence in the estimate of benefit and risk and may change the estimate.
- C** - Evidence from observational studies (eg, retrospective case series/reports providing significant impact on patient care), unsystematic clinical experience, or from potentially flawed randomized, controlled trials (eg, when limited options exist for condition). Any estimate of effect is uncertain.
- G** - Use has been substantiated by inclusion in at least one evidence-based or consensus-based clinical practice guideline.

Below the definitions, the page shows clinical information for 'Bronchiectasis, acute exacerbation' and 'Chronic obstructive pulmonary disease, acute exacerbation'. The 'Bronchiectasis' section states: 'Clinical experience suggests the utility of amoxicillin and clavulanate for the treatment of acute exacerbations of bronchiectasis'. The 'Chronic obstructive pulmonary disease' section states: 'Data from 2 randomized, double-blind studies support the use of amoxicillin and clavulanate for the treatment of bacterial exacerbations of chronic obstructive pulmonary disease (COPD)'. It also mentions: 'Based on the Global Initiative for Chronic Obstructive Lung Disease guidelines for the diagnosis, management, and prevention of COPD, amoxicillin and clavulanate is an effective and recommended treatment for COPD exacerbations'.

The text 'The content is align with the recommendation in UTD' is overlaid in red on the right side of the screenshot.

Administration and Storage

Noradrenaline [Norepinephrine] (Lexi-Drugs Multinational)

Outline [Expand All](#)

Administration and Storage Issues

Administration

Usual Infusion Concentrations:
Pediatric

Usual Infusion Concentrations: Adult
Administration: IV

Administration: Pediatric

Vesicant/Extravasation Risk

Storage/Stability

Preparation for Administration: Adult

Preparation for Administration: Pediatric

Compatibility

Monograph

Images

Adult Patient Education

Pediatric Patient Education

Preparation for Administration: Adult

Continuous IV infusion: Dilute with D5W, D5NS, or NS; dilution in NS is not recommended by the manufacturer; however, stability in NS has been demonstrated (Tremblay 2008). Concentrations ranging from 4 to 64 mcg/mL may be used in clinical practice (Phillips 2011; Walker 2010).

Preparation for Administration: Pediatric

Continuous IV infusion: Dilute with D5W, D5NS, or NS; dilution in NS is not recommended by the manufacturer; however, stability in NS has been demonstrated (Tremblay 2008). Concentrations ranging from 4 to 16 mcg/mL are typically used in clinical practice (Phillips 2011). ISMP and Vermont Oxford Network recommend a standard concentration of 16 mcg/mL for neonates (ISMP 2011).

Compatibility

See Triselle's IV Compatibility Database.

[Open Triselle's IV Compatibility](#)

Medication Safety Issues

Patient & Therapy Management

Noradrenaline [Norepinephrine] (Lexi-Drugs Multinational)

Outline [Expand All](#)

Warnings & Precautions

Reproduction, Pregnancy, & Lactation

Adverse Reactions

Adverse Reactions

Interactions

Metabolism/Transport Effects

Drug Interactions

Patient & Therapy Management

Monitoring Parameters

Nursing Considerations

Advanced Practitioners Physical Assessment/Monitoring

Nursing Physical Assessment/Monitoring

Monograph

Images

Adult Patient Education

Pediatric Patient Education

Monitoring Parameters

Blood pressure (or mean arterial pressure), heart rate; cardiac output (as appropriate), intravascular volume status, pulmonary capillary wedge pressure (as appropriate); urine output, peripheral perfusion; monitor infusion site closely

Consult individual institutional policies and procedures.

Advanced Practitioners Physical Assessment/Monitoring

Monitor blood pressure, heart rate, cardiac output, intravascular volume status, pulmonary capillary wedge pressure, urine output, and peripheral perfusion. Assess infusion site frequently for extravasation. Blanching along vein pathway is a preliminary sign of extravasation.

Nursing Physical Assessment/Monitoring

Check ordered tests and report abnormalities. Monitor vitals, fluid status (I & O), and cardiac status as ordered. Assess infusion site frequently for extravasation. Blanching along vein pathway is a preliminary sign of extravasation.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous:



Trastuzumab (AHFS Essentials (Adult and Pediatric))

概要

[U.S. Brand Names](#)[Therapeutic Class](#)[Black Box Warnings](#)[Special Alerts](#)[Introduction](#)[Uses](#)[Dosage and Administration](#)[Cautions](#)[Drug Interactions](#)[Pharmacokinetics](#)[Stability](#)[Actions](#)[Advice to Patients](#)[Preparations](#)[References](#)

專論

圖片

成人病患教育

Black Box Warnings

✓ Black box warning-under AHFS

Cardiotoxicity

- Risk of cardiotoxicity (e.g., ventricular dysfunction, CHF).^{Ref}
- Evaluate left ventricular function prior to and during therapy.^{Ref}
- Discontinuance of trastuzumab should be strongly considered in patients who develop a clinically important decrease in left ventricular function.^{Ref}

Anthracyclines and Cyclophosphamide

- Increased frequency and severity of cardiac toxicity when used in combination with an anthracycline and cyclophosphamide.^{Ref}

Hypersensitivity, Infusion, and Pulmonary Reactions

- Risk of severe (rarely fatal) hypersensitivity reactions, (e.g., anaphylaxis),^{Ref} infusion reactions, or severe pulmonary effects.^{Ref}
- Onset of symptoms generally occurs during or within 24 hours of initiation of the infusion.^{Ref}

Drug Interaction: Drug-Drug; Drug Allergy

Selected Items | Interaction Analysis

Drugs

Enter drug name

Aspirin
 Augmentin
 MetFORMIN

Allergies

Enter allergy name

Acetaminophen
 Eggs or Egg-derived Products

Duplicate Drug Therapy

Legend:

- A** = No known interaction
- B** = No action needed
- C** = Monitor therapy
- D** = Consider therapy modification
- X** = Avoid combination

Drugs in this analysis: Aspirin, Augmentin, MetFORMIN

View interaction detail by clicking on link.

Drug-Allergy Interactions

No interactions identified in the database

Drug-Drug Interactions

C [Aspirin \(Salicylates\) – MetFORMIN \(Agents with Blood Glucose Lowering Effects\)](#) *Depends on Dose*

Duplicate Therapy Interactions

No interactions identified in the database

About our Evidence Based content-IV Compatibility

The screenshot displays a software interface for evidence-based content-IV compatibility. It features a table with columns for Study, Drug 1, Vehicle 1, Drug 2, Vehicle 2, Solution, and Finding. A green 'C' icon in the first row indicates compatibility. A detailed view for 'Study 1' is shown, containing the following information:

- Study Period:** 24 hours.
- Containers:** Glass test tubes.
- Physical Compatibility:** Considered incompatible. See Notations. In this study, the appearance of precipitation depended on duration. No visible particulate matter appeared within 8 hours. However, visible particulates had formed by 24 hours.
- Storage Conditions:** Ambient room temperature near 23 °C exposed to fluorescent light.
- Methods:** Visual observation.
- Chemical Stability:** No information available.

The interface also includes a 'Selected Items' section, a 'Drugs' list with search and delete buttons, and an 'Analyze' button.

Drug Shortage

Lexicomp® Search Lexicomp User Guide Log Out

Home Trisese's IV Compatibility Interactions Drug I.D. Patient Education Calculators More Clinical Tools

< Back To Search Find in document Jump to Section Print Help

Calcium Folate [Leucovorin Calcium] (Lexi-Drugs Multinational)

Outline **Expand All**

- Drug Shortages: US
- Brand Names: International
- International Nonproprietary Names (INN)
- Brazilian Nonproprietary Names (DCB)
- Japanese Accepted Name (JAN)
- Anatomic Therapeutic Chemical (ATC) Classification
- Pharmacologic Category
- > Dosages
- > Uses

Monograph Images Adult Patient Education Pediatric Patient Education

Drug Shortages: US

One or more forms of this drug may be in short supply or unavailable. Refer to the following for additional information:

ASHP: <https://www.ashp.org/Drug-Shortages/Current-Shortages>

FDA: http://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Leucovorin%20Calcium%20Lyophilized%20Powder%20for%20Injection&st=c&camefrom=tabs-1

Brand Names: International

Acido Folinico/Leucovorina (CL); Anitrex (FI, PL, TW); Asovorin (AR); Cafona (TW); Cafonate (LK, PH); Calcium Folate (NZ); Calciumfolinat Faulding (SE); Calciumfolinat Pharnalink (SE); Calciumfolinat "Faulding" (DK); Calciumfolinat-Ebewe (PL, TW); Callonat (DK); Chemovorin (EG); Dalisol (MX); Estroquin (PE); Ferbon (KR); Folcasin (ID); Folical (CO); Folina 15 (TW); Folinato de Calcio Dakota Farma (PT); Kalcij-folinat (HR); Kuryrin (VN); Lederfolin (ES, IE, IT); Lederfoline (FR, PT); Ledervorin Calcium (BE, LU, NL); Leucan (ID); Leucocalcin (PY); Leuconolver (VE); Leucovorin (AE, AT, BG, CH, DE, GR, IE, JO, KW, PL, SA, TH, UY); Leucovorin Ca (PL); Leucovorin Calcium (AU, BB, CZ, HK, HN, ID, IN, MY, NZ, TH); Leucovorine Abic (NL); Lifacor (PH); Likelin (CN); Lovorin (PH); Medifolin (PT); Medsavorina (MX); MPL Coverin (PH); Novorin (ID); Nyirin (SG); Refolinon (GB, LU); Rescuovolin (BE, CH, DK, GR, KR, LU, SE, TH, TW); Robin (KR); Rontafur (AR); Tecnovorin (BR, EC)

Various Useful Calculators

Lexicomp[®]

Home

Calculators

Calculator Controls

Calculator Lookup

Search

Browse Category

- All
- All
- Adult
- Conversions
- Dental
- Emergency Drugs
- General
- Infusions
- International (SI Units)
- Pediatric
- Pharmacokinetics
- Renal Function Estimation
- Toxicology
- Abciximab
- Absolute Neutrophil Count

Opioid Agonist Conversion

Customize Calculator

DISCLAIMER: INFORMATION YOU RECORD ON THIS PAGE IS NOT VALID. ONLY DIGITS 0 TO 9 AND A SINGLE DECIMAL POINT "." ARE ACCEPTED. ANY OTHER CHARACTERS WILL RESULT IN AN INCORRECT RESULT.

Convert from mg/day

of

To

Calculate

Reset

Dose mcg/day

Note: Doses may need to be rounded to accommodate available tablets.

Calculator Lookup

Search

Category

Pharmacokinetics

Results

Level Prediction

Side Clearance Estimate

Sides: Dosing by Serum Levels

Sides: Empiric Dosing

Sides: Extended, Initial Dose

Sides: Extended, Interval Adjust

Level Prediction

Level Prediction

Dosing by Peak and Trough

Patient Education – 19 languages

Conditions, procedures, medications

成人泌尿道感染出院醫囑

Printed on 2020-06-07

You must carefully read the "Consumer Information Use and Disclaimer" below in order to understand and correctly use this information


Notice

您必須仔細閱讀以下的「消費者資訊之使用與免責聲明」，以瞭解並正確使用此資訊。

關於本主題

泌尿道感染的英文縮寫為 UTI，是因病菌侵入泌尿道而引起的。泌尿道（尿路）包括腎臟、輸尿管、尿道。尿液由此管流出。病菌可能進入尿道，然後繼續擴散到膀胱。輸尿管是連接膀胱和腎臟的管道。上部泌尿道感染則會引起腎臟感染。女性更常發生泌尿道感染 (UTI)。

腎臟如何運作



男性導尿管照護

Printed on 2020-06-07

You must carefully read the "Consumer Information Use and Disclaimer" below in order to understand and correctly use this information


Notice

您必須仔細閱讀以下的「消費者資訊之使用與免責聲明」，以瞭解並正確使用此資訊。

關於本主題

導尿管是一種軟管的裝置，使用它協助將尿液從膀胱排出體外。導尿管將您的膀胱連接到體外特製的貯袋。貯袋用來盛放排出的尿液，需定期將其倒空。您可能在短期內需要導尿管排尿。在您準備恢復做完全手術後，可能需使用導尿管。如果您的攝護腺肥大並影響您膀胱中的尿液，您可能需要長期使用導尿管。有時，攝護腺使用導尿管協助排尿。

男性導尿管




Lexicomp can do comparison for 4 drugs at the same time

The screenshot shows the Lexicomp website interface for a drug comparison. The top navigation bar includes 'Home', 'Trisef's IV Compatibility', 'Interactions', 'Drug I.D.', 'Patient Education', 'Calculators', and 'More Clinical Tools'. The main content area is titled 'Drug Comparisons - Monograph View' and features a search bar and 'Jump to Section' dropdown. Below the search bar, there are tabs for 'Search' and 'Results'. The comparison table is organized into sections: 'Brand Names: U.S.', 'Absorption', and 'Administration', each with a '(Top of page)' link. The table compares four drugs: Atorvastatin, Fluvastatin, Rosuvastatin, and Simvastatin.

Atorva\$TATin	Fluvastatin	Rosuvastatin	Simvastatin
Brand Names: U.S. (Top of page)			
Brand Names: U.S.Lipitor	Brand Names: U.S.Lescol XL	Brand Names: U.S.Crestor; Ezallor Sprinkle	Brand Names: U.S.FloLipid; Zocor
Absorption (Top of page)			
Absorption Oral: Rapidly absorbed; extensive first-pass metabolism in GI mucosa and liver			Absorption Although 85% is absorbed following administration, <5% reaches the general circulation due to an extensive first-pass effect
Administration (Top of page)			
Administration Oral: Administer with or without food; may take without regard to time of day. The	Administration Oral: Patient should be placed on a standard cholesterol-lowering diet before and during treatment	Administration Capsule: Oral: Administer with or without food	Administration Suspension: Administer in the evening on an empty stomach. Shake well for at least 20 seconds before

New Drug Reviews



A screenshot of a navigation menu with a blue header and white background. The header contains the text "More Clinical Tools" followed by a downward-pointing chevron. Below the header, there is a list of menu items: "Drug Comparisons", "Formulary Monograph Service", "MSDS", "Toxicology", "UpToDate®", "Indexes", "Other Clinical Links", and "Advanced Search". To the right of "Formulary Monograph Service", there is a sub-menu with four items: "P&T Formulary Reviews", "P&T Summary Reviews", "Drug Use Evaluations", and "New Drug Reviews". The "New Drug Reviews" item is highlighted in a darker blue, and a red arrow points to it from the right. A search icon is visible in a blue box to the right of the sub-menu.

New Drug Reviews

Chronological List

Explore the Chronological List Index

[New Drug Review - January 2021](#) New 12/18/20

[New Drug Review - December 2020](#) New 11/19/20

[New Drug Review - November 2020](#) New 10/23/20

[New Drug Review - October 2020](#) New 9/25/20

[New Drug Review - September 2020](#)

[New Drug Review - August 2020](#)

[New Drug Review - July 2020](#)

[New Drug Review - June 2020](#)

[New Drug Review - May 2020](#)

MSDS(Material Safety Data Sheets)

SECTION 4. FIRST AID MEASURES

If inhaled : Remove patient from exposure, keep warm and at rest. Obtain medical attention if ill effects occur.

In case of skin contact : Wash skin with soap and water.

In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes. Obtain medical attention if ill effects remain.

If swallowed : Provided the patient is conscious, wash out mouth with water and give 200-300 ml of water to drink.

SAFETY DATA SHEET



Version 3.1	Revision Date: 01.11.2017	SDS Number: 21043	Date of last issue: 30.05.2017 Date of first issue: 30.05.2017
----------------	------------------------------	----------------------	---

Most important symptoms and effects, both acute and delayed : Do NOT induce vomiting as a First-Aid measure. Obtain medical attention if ill effects occur. Refer to sections 2 and 11

Notes to physician : Symptomatic treatment and supportive therapy as indicated. Emergency medical treatment advice varies within different countries. For further information consult the Local National Poisons Information Services.

SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006



Version 3.1	Revision Date: 01.11.2017	SDS Number: 21043	Date of last issue: 30.05.2017 Date of first issue: 30.05.2017
----------------	------------------------------	----------------------	---

SECTION 1. IDENTIFICATION

1.1 Product Identifier

DURVALUMAB
Details of the supplier of the safety data sheet : ASTRAZENECA, P.O. Box 15437, Wilmington, DE 19893-5437, USA
Phone (24 hr.) Medical : (800) 296-9933
(24 hr.) Chemical/Spill/Emergency : INFOTRAC - (800) 535-5053
SafetyDataSheets.AlderleyPark@astrazeneca.com

Alternative Names
I5FRZ3
MEDA736
CAS No. : Not applicable

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Monoclonal antibody, Potential anti-cancer agent

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with 29 CFR 1910.1200
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
This is a monoclonal antibody and may have pharmacological effects. See Section 11.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous Ingredients

Chemical name	CAS-No.	Concentration (% w/w)
Durvalumab	1428935-60-7	>= 1 - < 10

SECTION 4. FIRST AID MEASURES

If inhaled : Remove patient from exposure, keep warm and at rest. Obtain medical attention if ill effects occur.

In case of skin contact : Wash skin with soap and water.

In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes. Obtain medical attention if ill effects remain.

If swallowed : Provided the patient is conscious, wash out mouth with water and give 200-300 ml of water to drink.

Advanced Search

Advanced Search Notification

Advanced Search routines can sometimes take up to several minutes to complete.

Limit to monograph section *

Adverse Reactions



Limit to database *

Lexi-Drugs Multinational



Search Lexicomp

bone marrow depression



COVID-19 vaccine tracker

Coronavirus Disease 2019 Vaccine Tracker (Lexi-Drugs Multinational)

Coronavirus Disease 2019 Vaccine Tracker

Candidate SARS-CoV-2 Vaccines in Advanced Clinical Trials: Key Aspects											
Compiled by John D. Grabenstein, MPH, PhD [All dates are estimates. All Days are based on first vaccination at Day 0.]											
Vaccine Sponsor (with Major Partners)	UxL of Oxford (Dennis Institute) with AstraZeneca	ModernaTX USA	BioNTech with Pfizer	Janssen & Johnson (Janssen Vaccines & Prevention)	Novavax	Sanoft Pasteur with GlaxoSmithKline	CureVac with Bayer	Candis BioLogics with Academy of Military Medical Sciences	Sinopharm (China National Biotec Group) (Beijing IBP, Wuhan IBP)	Sinovac Biotech Co.	Gamaleya Research Institute of Epidemiology & Microbiology
Headquarters	Oxford, England; Cambridge, England; Göttingen, Germany	Cambridge, Massachusetts	Marks, Germany; New York, New York	New Brunswick, New Jersey (Leiden, Netherlands)	Gaithersburg, Maryland	Lyon, France; Brentford, England	Tübingen, Germany	Tianjin, China; Beijing, China	Beijing, China; Wuhan, China	Beijing, China	Moscow, Russia
Product Designator	ChAdOx1 or AZD1222	mRNA-1273	BNT162b2, tozinameran, Comirnaty	Ad26.COV2.S, JFJ-78496733	NVX-CoV2373	TBA	CvxCov	Ad5-nCoV, Convidecia	BBIBP-CoV	CoronaVac	Siem-COVID-Vac (Jax-RoBIO, Bax), Sputnik V (Cynvax V)
Vaccine Type	Adenovirus Y23 vector	mRNA	mRNA	Adenovirus 26 vector	Subunit (spike) protein	Subunit (spike) protein	mRNA	Adenovirus 5 vector	Inactivated whole virus	Inactivated whole virus	Adenovirus 26 and adenovirus 5 vectors
Product Features	Chimpanzee adenovirus type Y23 vector	Within lipid nanoparticle dispersion	Within lipid nanoparticle dispersion	Human adenovirus type 26 vector	Adjuvanted with Matrix-M	Adjuvanted with A003 or AFO3	Adjuvanted with A003	Human adenovirus type 3 vector	Adjuvanted with aluminum hydroxide	Adjuvanted with aluminum hydroxide	Human adenovirus type 26 and type 5 vectors
Production Medium (origin)	HEK-293A (human embryo)	Cell free (synthetic)	Cell free (synthetic)	PER.C2 (human embryo)	Baculovirus/SF9 (insect)	Baculovirus/SF9 (insect)	Cell free (synthetic)	HEK-293 (human embryo)	Vero cells (monkey)	Vero cells (monkey)	Not reported
Route	IM	IM	IM	IM	IM	IM	IM	IM	IM	IM	IM
OFF Code	81302	81301	81300	81303							
CVX Code	310	207	208	212							
NDC Code	60310-1232-50	80777-0279-ee	09267-1000-ee	39676-0580-05							
Dosing Regimen	Single dose or Weeks 0 + 4-12	Days 0 + 28	Days 0 + 21	Single dose or Days 0 + 3E	Days 0 + 21	Days 0 + 21	Days 0 + 28	Single dose or Days 0 + 3E	Days 0 + 14 or Days 0 + 21	Days 0 + 14 or Days 0 + 28	Days 0 + 21
Expected Dose	5x10 ¹¹ viral particles in 0.5 mL (EU: NLT 2.5 x 10 ¹¹ infectious units)	100 mcg in 0.5 mL	80 mcg/0.3 mL (after dilution)	5x10 ¹¹ viral particles in 0.5 mL	5 mcg protein plus 50 mcg Matrix-M in 0.5 mL	5 or 15 mcg, T8D	6 or 8 mcg, T8D	5x10 ¹¹ or 1x10 ¹¹ viral particles	4 mcg	600 antigen units (IU) in 0.5 mL	1x10 ¹¹ viral particles per 0.5 mL

The logo consists of four colored squares: top-left blue with 'L', top-right green with 'I', bottom-left green with 'V', and bottom-right blue with 'E'. A white ECG line runs through the center of the squares.

online
LEXICOMP®





Wolters Kluwer★TW

好友人數 999,999 追蹤者 999,999

專門為台灣UTD/LCO使用者創立的群組




聊天



貼文





Create account

- Visit:

<https://www.lexi.com/account/create/>



Create Account

Fill out the fields below to create an account. Please note that all fields are required.

Account Details

FIRST NAME

LAST NAME

OCCUPATION

PRACTICE SETTING

HOW DO YOU HEAR ABOUT LEXICOMP?

COUNTRY

I AGREE AND ACKNOWLEDGE THAT, BY CREATING MY ACCOUNT, I AM OPTING IN TO RECEIVE EMAIL FROM LEXICOMP (A PART OF WOLTERS KLUWER), WHICH MAY INCLUDE PERIODIC NEWSLETTERS, PRODUCT UPDATES, NEWSLETTERS, WEBINAR INVITATIONS, AND SPECIAL OFFERS. I UNDERSTAND THAT I CAN OPT OUT AT ANY TIME.

Create Your Login

EMAIL ADDRESS

PASSWORD (MINIMUM 9 CHARACTERS)

CONFIRM PASSWORD

Create account



Create Account




Click on Log in now →
Enter email & Password →
Log in



My Account

Mobile App Account Management

Use these links to manage your Lexicomp mobile subscriptions, manage your devices, or update your profile information.



Adding Subscription code

Manage Account

log out

Ginger Chang [Edit information](#)

Your email address

Occupation: Nurse - Emergency Room

Practice Setting: Hospital

Country: Taiwan

Subscriptions

You don't have any subscriptions.

Add a Subscription by Purchasing From Our Web Store

Browse our selection of [drug information mobile apps](#) at our web store. Purchase one of our subscriptions and start accessing it from your mobile device today!

Add a Subscription by Code

Do I need a authorization code?
Customers that purchase online or by phone will not require a authorization code. An Authorization Code is a unique 12 digit alphanumeric code used to activate a Lexicomp subscription. Institutional users can obtain a authorization code directly from their site administrator or Lexicomp Online splash page (if applicable).

authorization code

Add Subscription



Remember to obtain your authorization code before this step

SCR9M6X4HEPP

Enter authorization Code →
Click on Add Subscription



Verify PIN

Wolters Kluwer
Clinical Drug Information

Your Lexicomp Mobile PIN

This is an autogenerated email to provide the PIN code for access to your Lexicomp Mobile subscription. Use the following to begin your subscription to Lexicomp Mobile:

PIN: [PIN]
Email Address: [Your email address]

Use the following URL to start your subscription: myaccount.lexi.com/activateCodePIN

If you have any questions or did not initiate this PIN generation, please contact us for more information or assistance at www.wolterskluwer CDI.com/support/ or

PIN letter will be sent to your e-mail

Sincerely,
The Lexicomp Mobile Team
Wolters Kluwer Clinical Drug Information

Manage Account

Logout

Your email address Edit information

Occupation: Nurse - Emergency Room
Practice Setting: hospital
Country: United States

Subscriptions

You don't have any subscriptions.

Add a Subscription by Purchasing From Our Web Store

Browse our selection of [drug information mobile apps](#) at our web store. Purchase one of our subscriptions and start working it from your mobile device today!

Verify PIN

To complete activation, we must verify your email address. A PIN has been sent to **Your email address**. Please check that email and enter the PIN to complete activation. **Your PIN will expire in 30 minutes.**

If you don't receive your PIN, you may need to [troubleshoot activation code](#).

Pin: [input field]
Verify

**Enter PIN ->
Click on Verify**

You create one account successfully!

Manage Account

[Log out](#)

Ginger Chang

Your email address

[Edit Information](#)

Occupation: Nurse - Emergency Room

Practice Setting: Hospital

Country: Taiwan

Subscriptions

You don't have any subscriptions.

Add a Subscription by Purchasing From Our Web Store

Browse our selection of [drug information mobile apps](#) at our web store. Purchase one of our subscriptions and start accessing it from your mobile device today!

Success

The subscription has successfully been added to your account. You may need to refresh or re-download the databases on your device.

Finish

Manage Account

[Log out](#)

Ginger Chang

Your email address

[Edit Information](#)

Occupation: Nurse - Emergency Room




Practice Setting: Hospital

Country: Taiwan

Subscriptions


Status	Product	Expiration
Active	Lexi-SELECT (Multinational)	1/1/2021

Log-in with mobile app





- ✓ You have to update all database first
- ✓ You can download Lexicomp as Offline into your mobile application for 2 devices per one account

How to update LCO content on Mobile App



- Hamburger Menu > list of content
- Same Content with new look
- Content need to be update

How to update LCO content on Mobile App



Select database
Then click update



A healthcare professional, likely a nurse or medical assistant, is shown in a clinical setting. She is wearing light purple scrubs and has a blue stethoscope around her neck. She is looking towards the left of the frame, possibly at a computer monitor. In the background, another person in blue scrubs is working at a desk. The scene is brightly lit, suggesting a window nearby. A blue semi-transparent banner is overlaid on the left side of the image, and a white box containing the Wolters Kluwer logo and name is positioned in the lower right area.

Thank You!



Wolters Kluwer